When does dinutuximab beta’s EU patent (and exclusivity) expire?
You are looking for the patent-expiry date in the European Union for dinutuximab beta (unituxin/beta product family). The exact expiry depends on which right you mean:
- the underlying patent(s) covering the active ingredient/manufacturing/use
- any supplementary protection certificate (SPC) in the EU
- data and market exclusivity granted under EU medicines rules (not the same thing as patent expiry)
To give a precise “EU patent expiry” date, I need the specific product name/strength and country (or the exact patent/SPC identifier you’re using). Patent and exclusivity timelines can differ across filings and jurisdictions, even if the medicine is the same.
What to check for EU “expiry” dates (patent vs SPC vs market exclusivity)
In EU practice, timelines often come from three separate tracks:
1) Patent expiry (from national/regional patent registers)
This is when a valid patent claim is no longer enforceable.
2) SPC expiry (if an SPC was granted)
SPCs extend patent protection for certain medicines to compensate for time lost before approval.
3) Regulatory exclusivity (data/market exclusivity)
These can delay generic/biosimilar competition even if patents expire later (or vice versa).
Is dinutuximab beta the same as unituxin (dinutuximab beta) in Europe?
Dinutuximab beta is the international nonproprietary name used for the approved anti-GD2 antibody used in high-risk neuroblastoma. “Unituxin” is commonly referenced for this product line, and “dinutuximab beta” is what you’ll see in regulatory and patent documents tied to that marketed medicine. If you share the exact marketed product details you have (marketing authorization holder or product code), I can align the correct filings.
Could biosimilars enter before all patents expire?
Yes, sometimes. Even if some patents remain, biosimilar entry can happen if a biosimilar company successfully avoids infringement (design-around), relies on non-protected aspects, or enters after the strongest blocking rights (often the core compound + any SPC + key method/use claims) expire. Conversely, litigation can delay launches despite regulatory readiness.
If you mean “EU patent expiry” for a specific competitor’s challenge, what matters?
If your goal is to predict when competitors can launch in the EU, you typically need to identify:
- which patent(s) are actually asserted or blocking (not every patent in the family)
- whether an SPC exists and its expiry date
- whether there are any national injunctions in key EU member states
What I need from you to answer with a specific date
Reply with one of the following so I can pinpoint the EU expiry accurately:
- the country you care about (e.g., EP/EMA coverage vs a specific EU member state), and the marketed product name/MAH you’re using, or
- any patent/SPC number (or a link to the register entry you’re looking at), or
- whether you mean patent expiry, SPC expiry, or regulatory data/market exclusivity.
Sources: none provided in your prompt, so I can’t reliably cite a specific expiry date yet.